<!doctype html>
<html lang="en">
  <head>
    <meta charset="utf-8" />
    <meta name="viewport" content="width=device-width, initial-scale=1" />
    <title>Home | BioCodeEthics</title>
    <link href="https://cdn.jsdelivr.net/npm/bootstrap@5.3.5/dist/css/bootstrap.min.css" rel="stylesheet" />
    <link rel="stylesheet" href="./styles.css" />
    <link href="https://fonts.googleapis.com/css2?family=Poppins:wght@300;400;500;600;700&display=swap" rel="stylesheet" />
    <style>
      body {
        padding-top: 70px;
      }
    </style>
  </head>
  <body>
    <!-- Navbar -->
    <nav class="navbar navbar-expand-lg fixed-top navbar-light bg-light text-uppercase">
      <div class="container">
        <a class="navbar-brand fw-bold" href="#">BioCodeEthics</a>
        <button class="navbar-toggler" type="button" data-bs-toggle="collapse" data-bs-target="#navbarNavAltMarkup">
          <span class="navbar-toggler-icon"></span>
        </button>
        <div class="collapse navbar-collapse" id="navbarNavAltMarkup">
          <div class="navbar-nav ms-auto">
            <a class="nav-link active px-lg-4" href="./index.html">Home</a>
            <a class="nav-link px-lg-4" href="./simulator.html">Simulator</a>
            <a class="nav-link px-lg-4" href="./legislature.html">Legislature</a>
            <a class="nav-link px-lg-4" href="./forum.html">Forum</a>
          </div>
        </div>
      </div>
    </nav>
    <!-- Header -->

    <header class="bg-light text-center py-5">
      <div class="container">
         </div>
    <!-- Welcome Section -->
    <div class="container mt-5">
      <div class="bg-black p-4 border rounded shadow-sm text-center welcome-section" style="background-image: url('./Images/GeneBackground.jpg'); background-size: cover; background-position: center; color: black;">
        
      </div>
    </div>
    <!-- Header Image -->
    <!-- Introduction -->
     <div class="container mt-5">
      


      

<!-- US Germline Gene Editing Laws Section -->
<div class="container mt-5">
  <div class="bg-white p-4 border rounded shadow-sm">
    <h2 class="h4 mb-3">ðŸ‡ºðŸ‡¸ US Germline Gene Editing Laws</h2>
    <ul class="mb-3 text-start" style="color: #111;">
      <li>
        <strong>Federal Restrictions:</strong> The U.S. bans the use of federal funds for research on human germline gene therapy. While no federal law outright bans all germline gene editing, Congress has enacted annual spending restrictions that prevent the FDA from considering clinical trial applications involving heritable genetic modifications in embryos. The Dickey-Wicker Amendment also prohibits federal funding for research involving the creation or destruction of human embryos.
      </li>
      <li>
        <strong>Private Funding:</strong> Privately funded germline gene editing research is not explicitly illegal, but any therapy intended for clinical use would still require FDA approval, which is currently blocked by federal spending restrictions.
      </li>
      <li>
        <strong>Ethical and Scientific Debate:</strong> The clinical use of germline gene editing is highly controversial due to unknown long-term risks and ethical concerns, especially since future generations cannot consent to the changes. After the 2018 announcement of gene-edited babies in China, U.S. scientists and policymakers called for a global moratorium on clinical germline editing. Some experts warn that a moratorium could stifle beneficial research, while others argue it is necessary to prevent unethical uses.
      </li>
      <li>
        <strong>Recent Research:</strong> U.S. scientists have used CRISPR to edit disease-causing genes in embryos for research only-these embryos are not implanted or brought to term.
      </li>
      <li>
        <strong>Public and NGO Views:</strong> Most advocacy and faith groups in the U.S. oppose germline editing, citing safety and ethical risks, though some support tightly regulated research on somatic (non-heritable) gene editing and mitochondrial replacement therapy.
      </li>
      <li>
        <strong>Regulatory Timeline Highlights:</strong>
        <ul>
          <li><strong>1996:</strong> Dickey-Wicker Amendment restricts federal funding.</li>
          <li><strong>2015:</strong> Congress attaches annual bans to FDA funding.</li>
          <li><strong>2017:</strong> National Academy of Sciences suggests clinical trials could be considered under strict conditions.</li>
          <li><strong>2018â€“2019:</strong> Calls for global moratorium and international standards after Chinese gene-edited babies.</li>
        </ul>
      </li>
    </ul>
    <div class="alert alert-info mb-4" style="color: #111; background-color: #e9f7fd; border-color: #b8e2fb;">
      <strong>Bottom line:</strong> Germline gene editing is effectively prohibited in the U.S. for clinical use, especially with federal funds, due to ethical, legal, and safety concerns. Privately funded research is possible but cannot move to clinical trials under current law, and the debate over whether to allow or regulate such research continues.
    </div>
    <div class="text-center">
      <img src="./Images/map.png" alt="US Germline Gene Editing Laws Map" class="img-fluid rounded border" style="max-width: 700px; width: 100%; height: auto;">
      <p class="text-muted mt-2" style="font-size: 0.95rem;">
        Source: 
        <a href="https://crispr-gene-editing-regs-tracker.geneticliteracyproject.org/united-states-embryonic-germline-gene-editing/" 
           target="_blank" rel="noopener" style="color:#111;">
          Genetic Literacy Project
        </a>
      </p>
    </div>
  </div>
</div>


<!-- UK Germline Gene Editing Laws Section -->






    <!-- Footer -->
    <footer class="text-center mt-5 py-3 bg-light">
      <p>&copy; 2025 BioCodeEthics</p>
    </footer>

    <!-- Scripts -->
    <script src="https://cdn.jsdelivr.net/npm/bootstrap@5.3.5/dist/js/bootstrap.bundle.min.js"></script>
  </body>
</html>
